Miller Discusses the Use of Selinexor in TP53 Wild-Type Advanced Endometrial Cancer

Season 10 Episode 47  ·  Jul 25, 2024, 09:25 PM

Headliner
Share
Subscribe

Dr Miller discusses findings from the SIENDO trial of selinexor maintenance therapy in patients with TP53 wild-type advanced endometrial cancer.

Share
Subscribe
Next
Pegram Details the Use of Oral SERDs in ESR1+ Metastatic Breast Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air